



**LUNGMAP NGS Testing Reference Page**  
**Approved Commercial and Academic Laboratories**  
*As of [05/19/2026]*

**Approved tissue-based NGS testing laboratories include:**

<b>Commercial Laboratories</b>	<b>Assay Names</b>
BostonGene	Tumor Portrait Test
Caris Life Sciences	MI Cancer Seek
Caris Life Sciences	MI Tumor Seek Hybrid
Exact Sciences, Inc.	OncoExTra
Foundation Medicine	FoundationOne CDx
Genomic Testing Cooperative	Solid Tumor Profile
Guardant	Guardant360 TissueNext (498 gene panel)
The Jackson Laboratory	SOMASEQ
Labcorp Oncology	OmniSeq INSIGHT
Myriad Genetics	Precise Tumor
Natera	Altera
NeoGenomics Laboratories	Neo Comprehensive – Solid Tumor/NEO PanTracer Tissue
NeoGenomics Laboratories	NeoTYPE DNA + RNA Lung
PathGroup Oncology	Endeavor
PathGroup Oncology	SmartGenomics Complete
Personal Genome Diagnostics	elio Tissue Complete
Quest Diagnostics Inc.	Solid Tumor Expanded Panel
siParadigm Diagnostic Informatics	siPortfolio, Comprehensive NGS
Strata Oncology	Strata Select
Tempus	xT Solid Tumor

<b>Academic Laboratories</b>	<b>Assay Names, if necessary</b>
Augusta University	
Brigham and Women's Hospital	
Cedars-Sinai Medical Center	
Children's Hospital of Philadelphia	
City of Hope National Medical Center	
Columbia University	
Dana-Farber Cancer Institute	
Dartmouth Health	DHCancerSeq v2
Fox Chase Cancer Center	
Frederick National Laboratory for Cancer Research	
Johns Hopkins Genomics	
Knight Diagnostic Laboratories at Oregon Health & Science University	
Massachusetts General Hospital	
Memorial Sloan Kettering Cancer Center	
Moffitt Cancer Center	
National Cancer Institute – Laboratory of Pathology	
Northwestern Medicine	Expanded Solid Tumor NGS Panel
Providence Genomics	
Stanford Health Care	



Texas Children's Hospital	
The University of Texas MD Anderson Cancer Center	
University of California San Francisco	
University of Chicago	
University of Colorado	
University of Illinois Chicago	
University of Kansas	Comprehensive Cancer Targeted Gene Panel
University of Michigan	
University of Washington	
Weill Cornell Medicine	
Yale University	

**Approved blood-based (ctDNA) NGS testing laboratories include:**

<b>Commercial Laboratories</b>	<b>Assay Names</b>
Foundation Medicine	FoundationOne Liquid CDx
Guardant	Guardant360 (740 gene panel)
Tempus	xF+ (523 gene panel)



**Disapproved\* tissue-based NGS testing laboratories for general use on LUNGMAP include:**

<b>Laboratories</b>	<b>Assay Names</b>
Advocate Clinical Laboratories IL Central Lab	Next Generation Sequencing Solid Tumor Panel 50 (ONCO50)
Advocate Clinical Laboratories IL Central Lab	Solid Tumor 159 Genes NGS Panel (LAB12423)
Allina Health Laboratory	Allina Lung Non-Small Cell Carcinoma Targeted NGS Panel
Baptist Health Pathology and Cytology Laboratories	PCL Rapid Cancer Panel
Circulogene Theranostics	TumorClear NGS Panel
Emory Warner Pathology Laboratories	Expanded Cancer Mutation Profile
GenPath Oncology	OnkoSight Advanced Lung Cancer
Guardant	Guardant360 TissueNext (84 gene panel)
Hartford Hospital Laboratory	NGS Solid Tumor Combined Variant Plex and RNA Fusion Panel (based on ArcherDX)
Kaiser Permanente Mid-Atlantic	KPMAS Precision NGS Panel (~45 DNA genes, plus CNV and Fusion)
Lahey Hospital and Medical Center	The Lahey Solid Tumor DNA NGS Test
Medical University of South Carolina	Solid Tumor Mutation Panel (49 gene panel)
Quest Diagnostics Inc.	Comprehensive LungSEQPlus
Quest Diagnostics Inc.	LungSEQ Concurrent Panel
Virginia Commonwealth University (VCU Health)	Oncogenomic Solid Tumor v2
Washington University in St. Louis	GatewaySeq NGS Panel

**\*Please note if these tests show the presence of a sub-study biomarker, they may still be eligible for use on a matched sub-study (S1900X), but not for a non-matched sub-study (S1800X).**

**Disapproved blood-based NGS testing laboratories for general use on LUNGMAP include:**

<b>Laboratories</b>	<b>Assay Names</b>
Guardant	Guardant360 CDx (74 gene panel)
Tempus	xF (105 gene panel)



## Criteria for Use of a NGS-based Test NOT on the List of Approved Tests

If a potential participant has results from a CLIA, ISO/IEC or CAP approved NGS-based test that is not on the approved list above, the test may be allowable for participation in **LUNGMAP**. For inquiries regarding a test that is **not** on the approved list above, please e-mail [LUNGMAPNGS@swog.org](mailto:LUNGMAPNGS@swog.org) with a copy of the test results and documentation of the list of alterations included in the test (See instructions in **LUNGMAP** Section 15.4).

Acceptable NGS testing reports must contain evidence of successful testing for the presence or absence of the following tumor genomic alterations:

- ALK rearrangement/fusion
- BRAF V600E mutation
- BRAF other mutation
- CUL3 mutation (optional)
- EGFR exon 19 deletion
- EGFR exon 20 insertion
- EGFR exon 21 L858R mutation
- EGFR other mutation
- ERBB2 (HER2) amplification/copy number gain
- ERBB2 (HER2) mutation
- KEAP1 mutation
- KRAS G12C mutation
- KRAS other mutation
- MET amplification/copy number gain
- MET exon 14 skipping mutation/splice site alteration
- MET other mutation
- NFE2L2 mutation
- NTRK1 rearrangement/fusion
- NTRK2 rearrangement/fusion
- NTRK3 rearrangement/fusion
- RET rearrangement/fusion
- ROS1 rearrangement/fusion
- STK11 mutation
- TP53 mutation

Data will be collected on the **LUNGMAP** Genomic Alterations Form in Rave. Please note that this list may not be exhaustive of the full set of required alterations.